Primary Breast Lymphoma: Exceptional Lesion with Particular Management

Olfa El Amine El Hadj1, Azza Gabsi2, Aida Goucha1, Meyssa Belghith1, Khaled Rahal3 and Amor Gamoudi1

1Department of Pathology, Carcinological Institute Salah Azaiez, Tunisia
2Department of Medicine, Carcinological Institute Salah Azaiez, Tunisia
3Surgical Department, Surgical Department Salah Azaiez, Tunisia

Abstract

Introduction: Non-Hodgkin’s primary lymphoma of the breast is a rare entity. These tumors represent 0.04% to 0.2% of malignant breast pathology, 2.2% of extranodal lymphoma and 0.4% of all non-Hodgkin lymphoma. Clinical and radiological aspects show no special characteristics. The diagnosis is based on the presence of a lymphomatous proliferation strongly associated to the breast tissue and the diagnosis of an extra-mammary lymphoma must be removed except the presence of ipsilateral axillary lymphadenopathy.

Patients and methods: This is a retrospective study of 9 patients treated for non-Hodgkin’s primary lymphoma of the breast. They were collected over a period of 14 years (2000-2013). They interested 1 case of follicular lymphoma, 1 case of large T-cell lymphoma and 7 cases of large B-cell lymphoma. The average age was 50 years, ranging between 30 to 76 years. The sex ratio was 0.11 (1 man/8 women). The median follow-up was 43 months (4-192). Six patients were older than 60 years. All the tumors were architecturally diffuse. The overall survival was 100% at one year 60% at 3 years. Seven patients achieved a complete remission after initial treatment; one had relapsed after 2 months. Among the 7 cases of large B cell lymphoma, two cases result from follicular lymphoma’s transformation. The average processing time was 17 months.

Conclusion: The primary breast lymphoma is often diagnosed late. Treatment should be rapidly implemented. Indeed, the 5-year survival of stage I of the Ann Arbor classification is better than for stage II.

Keywords: Breast; Non-Hodgkin lymphoma; Histology; Immunohistochemistry

Introduction

Primary breast lymphoma (PBL) is defined as the affection of one or both breasts. Lymphomatous proliferation should be strongly associated to the breast tissue and the diagnosis of an extra-mammary lymphoma must be removed except the presence of ipsilateral axillary lymphadenopathy. Wiseman and Liao first defined PBL according to four criteria [1] the close anatomic proximity of mammary and lymphomatous tissue, absence of a previous diagnosis of an extra-mammary lymphoma, lack of evidence of a disseminated disease (except for the ipsilateral axillary nodal involvement) and an adequate quality of the histopathological specimen. These criteria are still widely accepted. PBL represents only 0.04% to 0.52% of breast malignancies, 2.2% of extranodal lymphomas and 0.4% all non-Hodgkin’s lymphoma [2,3]. We propose in this work to review clinico-pathological characteristics and therapeutic particularities of non-Hodgkin primary lymphoma of the breast.

Patients and Methods

This is a retrospective study of 9 patients treated for non-Hodgkin’s primary lymphoma of the breast. They were collected over a period of 14 years (2000-2013). Data on patient characteristics, the management procedures and evolution were collected from medical records and information sheets. This study concerns patients with a pathologic diagnosis of breast lymphoma. An extra-mammary location has been eliminated in all cases.

Results

The average age of patients was 50 years, ranging between 30 to 76 years. The population analyzed showed a female predominance (8 female with only one male).

In our study, three patients had breast pathology history. One patient had a history of an intra-ductal carcinoma. Two patients had a history of breast primitive follicular lymphoma which degenerates on diffuse large B cell lymphoma after 2 years and 10 months of evolution. One patient had a family history of infiltrating ductal carcinoma reported in a paternal aunt and a cousin. Three patients were already postmenopausal for 10, 15 and 21 years, while 5 patients were still in childbearing age. One of our patients was under hormonal contraception for seven years. One of our patients, aged 30 years old, was pregnant for five months at the moment of breast lymphoma diagnosis.

The PBL discovery circumstances were mammary masses, increasing the volume of the breast and skin inflammatory signs. This pathology has interested the right side in 3 patients and left side in 5 patients. It was bilateral, at diagnosis, in only one patient. The most frequent location was the left upper outer quadrant in 5 patients, and the super-outer quadrant right in one case.

The average clinical size was 6.4 cm, up to a maximum of 15 cm. It was more than 5 cm in 3 patients. The ipsilateral axillary lymph nodes

Keywords: Breast; Non-Hodgkin lymphoma; Histology; Immunohistochemistry

Introduction

Primary breast lymphoma (PBL) is defined as the affection of one or both breasts. Lymphomatous proliferation should be strongly associated to the breast tissue and the diagnosis of an extra-mammary lymphoma must be removed except the presence of ipsilateral axillary lymphadenopathy. Wiseman and Liao first defined PBL according to four criteria [1] the close anatomic proximity of mammary and lymphomatous tissue, absence of a previous diagnosis of an extra-mammary lymphoma, lack of evidence of a disseminated disease (except for the ipsilateral axillary nodal involvement) and an adequate quality of the histopathological specimen. These criteria are still widely accepted. PBL represents only 0.04% to 0.52% of breast malignancies, 2.2% of extranodal lymphomas and 0.4% all non-Hodgkin’s lymphoma [2,3]. We propose in this work to review clinico-pathological characteristics and therapeutic particularities of non-Hodgkin primary lymphoma of the breast.

Patients and Methods

This is a retrospective study of 9 patients treated for non-Hodgkin’s primary lymphoma of the breast. They were collected over a period of 14 years (2000-2013). Data on patient characteristics, the management procedures and evolution were collected from medical records and information sheets. This study concerns patients with a pathologic diagnosis of breast lymphoma. An extra-mammary location has been eliminated in all cases.

Results

The average age of patients was 50 years, ranging between 30 to 76 years. The population analyzed showed a female predominance (8 female with only one male).

In our study, three patients had breast pathology history. One patient had a history of an intra-ductal carcinoma. Two patients had a history of breast primitive follicular lymphoma which degenerates on diffuse large B cell lymphoma after 2 years and 10 months of evolution. One patient had a family history of infiltrating ductal carcinoma reported in a paternal aunt and a cousin. Three patients were already postmenopausal for 10, 15 and 21 years, while 5 patients were still in childbearing age. One of our patients was under hormonal contraception for seven years. One of our patients, aged 30 years old, was pregnant for five months at the moment of breast lymphoma diagnosis.

The PBL discovery circumstances were mammary masses, increasing the volume of the breast and skin inflammatory signs. This pathology has interested the right side in 3 patients and left side in 5 patients. It was bilateral, at diagnosis, in only one patient. The most frequent location was the left upper outer quadrant in 5 patients, and the super-outer quadrant right in one case.

The average clinical size was 6.4 cm, up to a maximum of 15 cm. It was more than 5 cm in 3 patients. The ipsilateral axillary lymph nodes
lymph nodes of 2 to 4 cm in diameter, a large right parietal mass of 11 cm and a multinodular splenomegaly. In our study 5 patients had stage I at diagnosis and 4 patients had stage II (Table 1).

By histological exam, 7 cases correspond to a large B-cell lymphoma (LBCL) (Figure 1), a case of follicular lymphoma and one case of large T-cell lymphoma. Immunohistochemical study allowed us to confirm the diagnosis of non-Hodgkin’s lymphoma. We used a large panel of antibodies: B marker (CD20), T marker (CD3), CD30, CD45, CD15 and CD10. In cases of LBCL, the I.H.C study showed a diffuse and intense staining with anti-CD20 (Figure 1). In case of T cell lymphoma, the tumor cells expressed diffusely the anti CD3. In follicular lymphoma, we found a diffuse expression of anti CD 20 and CD 10. Details of immunohistochemical results are summarized in Table 2. Treatment consisted on surgery, chemotherapy and/or radiotherapy. Five patients had only chemotherapy; four had chemotherapy with radiotherapy. One patient had received radiotherapy alone (Table 1). The surgery was performed in 7 cases. Five patients had a lumpectomy with axillary dissection while 2 had a radical surgery mastectomy with axillary dissection type Patey. Progression free survival was 43% at 3 years and 24% at 5 years. The median follow-up of our patients was 41 months with extremes ranging from 1 to 159 months. Overall survival was 60% at 3 years and 42% at 5 years.

**Discussion**

The term “primary breast lymphoma” (PBL) is used to define a malignant lymphoma primarily occurring in the breast in the absence of previously detected lymphoma localizations. It occurs specially in women whose median age is between the fifth and sixth decade [4,5]. Only a few cases have been reported in males [6]. In this report 8 patients among 9 were females. PBL is also a tumor of elderly women [2,3]. However, some authors have shown that a median of 28 years was found in 15% of cases in pregnant women or during breast-feeding [7]. In our study, a patient with DBCL was 30-year-old and was pregnant at the fifth month.

The association lymphoma and pregnancy is increasingly described and some authors have found that it is more important than pregnancy-carcinoma association. Thus, we can conclude that hormonal disturbances likely play a role of inducing proliferation lymphoma [7].

The affection is often unilateral. In 18% of cases, it is bilateral; it can be simultaneous (12%) or sequential (6%) [8,9]. The mode of revelation is almost always a breast tumor with an inflammatory mastitis [2]. The axillary lymph nodes are found in 20% to 40% of cases [10].

The primitive character of breast lymphoma is based on clinical investigation. Indeed, we should eliminate secondary breast’s invasion during the natural evolution of non-Hodgkin lymphoma [11].

The radiologic imaging’ aspects are nonspecific. Mammogram often shows a well limited mass with homogeneous density and benign

<table>
<thead>
<tr>
<th>Patient</th>
<th>Stage</th>
<th>Histological Type</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>I</td>
<td>Diffuse large B cell Lymphoma</td>
<td>Chemotherapy-Radiotherapy</td>
</tr>
<tr>
<td>2</td>
<td>I</td>
<td>Diffuse large B cell Lymphoma</td>
<td>Chemotherapy-Radiotherapy</td>
</tr>
<tr>
<td>3</td>
<td>I</td>
<td>Diffuse large B cell Lymphoma</td>
<td>Chemotherapy-Radiotherapy</td>
</tr>
<tr>
<td>4</td>
<td>I</td>
<td>Diffuse large B cell Lymphoma</td>
<td>Chemotherapy-Radiotherapy</td>
</tr>
<tr>
<td>5</td>
<td>II</td>
<td>Diffuse large B cell Lymphoma</td>
<td>Chemotherapy</td>
</tr>
<tr>
<td>6</td>
<td>II</td>
<td>Diffuse large B cell Lymphoma</td>
<td>Chemotherapy</td>
</tr>
<tr>
<td>7</td>
<td>II</td>
<td>Diffuse large B cell Lymphoma</td>
<td>Chemotherapy</td>
</tr>
<tr>
<td>8</td>
<td>I</td>
<td>Follicular Lymphoma</td>
<td>Radiotherapy</td>
</tr>
<tr>
<td>9</td>
<td>II</td>
<td>Large T cell Lymphoma</td>
<td>Chemotherapy</td>
</tr>
</tbody>
</table>

Table 1: details of therapeutic options received by the 9 patients included in the study.
appearance, evoking a cyst, a fibroadenoma or phylloides tumor. Less frequently, it is a mastitis appearance with diffuse increase breast density or an ill-defined or speculated contour mass [12]. Rarely, a suspicious aspect of malignancy is observed, but there is never stellar opacity or microcalcifications [10]. Ultrasound presentation is not specific, usually as a hypoechoic and homogenous mass, with regular contours. Rarely a mastitis appearance is seen on ultrasound. The discrepancy between alarming clinical presentation and reassuring mammography may suggest the diagnosis [10].

The standard histological examination left little doubt in case of medullary and anaplastic carcinoma whereas lymphoma’s diagnosis is often difficult [13,14]. Usually, immunohistochemical study on paraffin sections confirms the diagnosis [15]. Diffuse large B-cell lymphoma is the most frequent subtype. It represents 45% to 80% of all breast lymphomas subtypes. All histological types have been described in breast. Lymphoma of the MALT type marginal zone are common (0% to 44%) and Burkitt’s lymphoma often associated with bilateral involvement [16]. In our work, no cases of Burkitt’s lymphoma has been described can be related to a particular geographical distribution of this type of lymphoma [13,14].

The management strategies for PBL vary broadly, from surgical intervention to combination chemotherapy and radiotherapy. However, there is no up to date standard guideline for PBL treatment. Mastectomy for PBL is not well-supported because it shows neither improved survival nor reduced risk of recurrence. Several studies have recommended that minimally invasive surgery is the preferable option because extensive surgery may carry a high risk of morbidity. Also, axillary dissection adds no therapeutic advantage [17]. At present, early stages of PBL can be successfully treated with combination therapy, in which CHOP regimen is the most common chemotherapeutic agent. Several investigators have recommended a treatment regimen involving combination chemotherapy with or without radiation therapy [17].

Ganjoo et al. [18] searched the Stanford lymphoma database for patients with documented lymphoma involving the breast between 1981 and 2005 and included 37 patients in their analysis. Their DLBCL patients received doxorubicin-based chemotherapy, with 70% receiving involved-field radiotherapy (IFRT) with doses of 3600-5040 cGy. A single patient additionally received cytotoxic intrathoracic therapy. No recurrences occurred in the involved breast. Among the DLBCL patients, 5-year progression-free survival (PFS) was 61%, with a median follow-up of 3.8 years (range: 3 months to 19 years) and a 5-year OS was estimated at 82%. Patients with indolent lymphoma had an estimated 5-year PFS of 76% and an OS of 92%. The authors conclude that DLBCL of the breast can be successfully treated with doxorubicin-based chemotherapy alone or with IFRT.

In 2008, Ryan et al. [19] published the results of a retrospective international study of 204 eligible patients with PBL DLBCL.

### Table 2: Details of immunohistochemical profile of 9 primary breast lymphomas.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Histological Type</th>
<th>CD20</th>
<th>CD45</th>
<th>CD3</th>
<th>CD30</th>
<th>CD15</th>
<th>CD10</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Diffuse large B cell Lymphoma</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>2</td>
<td>Diffuse large B cell Lymphoma</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>3</td>
<td>Diffuse large B cell Lymphoma</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>4</td>
<td>Diffuse large B cell Lymphoma</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>5</td>
<td>Diffuse large B cell Lymphoma</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>6</td>
<td>Diffuse large B cell Lymphoma</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>7</td>
<td>Diffuse large B cell Lymphoma</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>8</td>
<td>Follicular Lymphoma</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>9</td>
<td>Large T cell Lymphoma</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Study Group-affiliated institutions from 1980 to 2003. The median age was 64 years, median OS was 8.0 years, and median progression-free survival (PFS) was 5.5 years. There was no benefit from mastectomy, as opposed to biopsy or lumpectomy. At a median follow-up time of 5.5 years, in 35% of patients the tumour had progressed: 16% locally in the same or contralateral breast, 5% in the CNS and 14% in other extranodal sites. According to the authors, the combination of limited surgery, anthracycline-containing chemotherapy, and involved-field RT produced the best outcome in the pre-rituximab era. In conclusion, they postulated that a combined therapy was the best method of treating patients with PBL. They suggested using prophylaxis to avoid central nervous system involvement. A similar opinion was expressed by Aviles et al. [20].

The prognosis of diffuse large B-cell lymphoma is poor. Among 215 cases whose outcome was known, Prevot [19] notes that more than half of the patients died within a period ranging from 4 days to 178 months after diagnosis. Ballali estimated survival rate at 5-year 30% to 50%. [20] Histological type and clinical stage of the disease are the two main prognostic factors. Indeed, the risk of death is nearly double if PBL stage II versus stage I [21-23].

### Conclusion

Primary lymphoma is a very rare pathology. If symptoms are not yielding to treatment, histological sampling is imperative. Treatment should be quickly implemented. Indeed, the five-year survival for stage I of the classification of Ann Arbor is better than for stage II.

### References


J Cancer Sci Ther, an open access journal
ISSN: 1948-5956
Volume 8(12) 294-2 (2016) - 296


